Медицинская литература. Новинки

 

 

 

 

 

 

Гепатоспецифичность контрастного препарата Примовист в дифференциальной диагностике очаговых заболеваний печени и желчных путей

Вы можете загрузить полный текст статьи в формате pdf

Ключевые слова:

Литература:
1. Hammerstingl R., Huppertz A., Breuer J., Balzer T., Blake0
borough A., Carter R., Lluis Castells F.L., Heinz0Peer G.,
Judmaier W., Laniado M., Manfredi R.M., Mathieu D.G.,
Muller D., Mortele K., Reimer P., Reiser M.F., Robinson P.J.,
Shamsi K., Strotzer M., Taupitz M., Tombach B., Valeri G.,
Bernhard E., van Beers B.E., Vogl T.J. Diagnostic efficacy of
gadoxetic acid (Primovist)!enhanced MRI and spiral CT for
a therapeutic strategy: comparison with intraoperative and
histopathologic findings in focal liver lesions. Eur. Radiol. 2008;
18 (3): 457–467.
2. Schneider G., Grazioli L., Sain S. MRI of the Liver. Springer.
2006. Р. 253–274.
3. Егоренков В.В. Лечение злокачественных опухолей печени с
применением методов локальной деструкции (химическая
аблация, радиочастотная аблация, криодеструкция). Практическая онкология. 2008; 9 (4): 202–208.
4. Пахмутова Ю.А. Выбор метода диагностики и хирургического лечения доброкачественных очаговых поражений печени: дис. … канд. мед. наук. СПб., 2009. 131 с.
5. Панфилова Е.А., Давыденко П.И., Чжао А.В., Кармазановский
Г.Г. Современные возможности лучевой диагностики метастатического поражения печени. Мед. виз. 2011; 6: 38–42.
6. Kuszyk B.S., Bluemke D.A., Urban B.A., Choti M.A., Hruban R.H.,
Sitzmann J.V., Fishmann E.K. Portal!phase contrastenhanced
helical CT for the detection of malignant hepatic tumors: sensitivity based on comparison with intraoperative and pathologic
findings. Am. J. Roentgenol. 1996; 166 (1): 91–95.
7. Bonaldi V.M., Bret P.M., Reinhold C.M. Helical CT of the liver:
value of an early hepatic arterial phase. Radiology. 1995; 197 (1):
357–363.
8. Hollett M.D., Jeffrey R.B., Nino0Murcia M., Jorgensen M.J.,
Harris D.P. Dual!phase helical CT of the liver: value of arterial
phase scans in the detection of small (1.5 cm) malignant hepatic neoplasms. Am. J. Roentgenol. 1995; 164 (4): 879–884.
9. Van Hoe L., Baert A.L., Gryspeerdt S., Vandenbosh G., Nevens F.,
Van Steenbergen G., Marchal G. Dual!phase helical CT of the
liver: value of an early!phase acquisition in the differential diagnosis of noncystic focal lesions. Am. J. Roentgenol. 1997;
168 (5): 1185–1192.
10. Paulson E.K., McDermott V.G., Keogan M.T., De0Long D.M.,
Frederick M.G., Nelson R.C. Carcinoid metastases to the liver: role
of triple phase helical CT. Radiology. 1998; 206 (1): 143–149.
11. Pawluk R.S., Tummala S., Brown J.J., Borrello J.A. A retrospective analysis of the accuracy of T2!weighted images and dynamic
gadoliniumenhanced sequences in the detection and characterization of focal hepatic lesions. Magn. Reson. Imaging. 1999; 9
(2): 266–273.
12. Ward J., Naik D., Guthrie A., Wilson D., Robinson P.J. Hepatic
lesion detection: comparison of MR imaging after administration of superparamagnetic iron oxide with dual-phase CT by
using alternative!free response receiver operating characteristic
analysis. Radiology. 1999; 210 (2): 459–466.
13. Semelka R.C., Martin D.R., Balci C., Lance T. Focal liver lesions:
comparison of dual!phase CT and multisequence multiplanar
MR imaging including dynamic gadolinium enhancement.
Magn. Reson. Imaging. 2001; 13 (3): 397–401.
14. Winterer J.T., Kotter E., Ghanem N., Langer M. Detection and
characterization of benign focal liver lesions with multislice CT.
Eur. Radiol. 2006; 16 (11): 2427–2443.
15. Petersein J., Spinazzi A., Giovagnoni A., Soyer P., Terrier F., Lenci0
oni R., Bartolozzi C., Grazioli L., Chiesa A., Manfredi R., Marano P.,
Van Persijn Van Meerten E.L., Bloem J.L., Petre C., Marchal G.,
Greco A., McNamara M.T., Heuck A., Reiser M., Laniado M.,
Claussen C., Daldrup H.E., Rummeny E., Kirchin M.A., Piro0
vano G., Hamm B. Focal liver lesions: evaluation of the efficacy
of gadobenate dimeglumine in MR imaging!a multicenter phase
III clinical study. Radiology. 2000; 215 (3): 727–736.
16. Ros P.R., Freeny P.C., Harms S.E., Seltzer S.E., Davis P.L.,
Chan T.W., Stillman A.E., Muroff L.R., Runge V.M.,
Nissenbaum M.A. Hepatic MR imaging with ferumoxides: a multicenter clinical trial of the safety and efficacy in the detection of
focal hepatic lesions. Radiology. 1995; 196 (2): 481–488.
17. Torres C.G., Lundby B., Tufte S.A., McGill S., Gordon P.B., Bjerknes
H.S. MnDPDP for MR imaging of the liver: results from the
European phase III studies. Acta Radiol. 1997; 38 (4): 631–637.
18. Kim Y.K., Lee J.M., Kim C.S., Chung G.H., Kim C.Y., Kim I.H.
Detection of liver metastases: gadobenate dimeglumine!
enhanced three!dimensional dynamic phases and one!hour
delayed phase MR imaging versus superparamagnetic iron oxide-enhanced MR imaging. Eur. Radiol. 2005; 15 (2): 220–228.
19. Simon G., Link T.M., Wortler K., Doebereiner F., Schulte0
Frohlinde E., Daldrup0Link H., Settles M., Rummeny E.J.
Detection of hepatocellular carcinoma: comparison of Gd-DTPA and ferumoxides!enhanced MR imaging. Eur. Radiol.
2005; 15 (5): 895–903.
20. Vogl T.J., Kummel S., Hammerstingl R., Schellenbeck M., Schu0
macher G., Balzer T., Schwarz W., Muller P.K., Bechstein W.O.,
Mack M.G., Sollner O., Felix R. Liver tumors: comparison of MR
imaging with Gd!EOB!DTPA and Gd!DTPA. Radiology. 1996;
201 (1): 59–67.
21. Reimer P., Rummeny E., Shamsi K., Balzer T., Daldrup H.,
Tombach B., Hesse T., Berns T., Peters P. Phase II clinical evaluation of Gd-EOBDTPA: dose, safety aspects and pulse
sequence. Radiology. 1996; 199 (1): 177–183.
22. Шимановский Н.Л., Кулаков В.Н., Григорьева В.Ю., Липен0
гольц А.А. Наноразмерные частицы оксида железа для диагностики и гипертермической терапии в онкологии. Российский биотерапевтический журнал. 2011; 10 (2): 25–32.
23. Schering A.G. Product monograph. Berlin, 2005. Р. 1–40.
24. Nakamura Y., Awai K., Ohmoto T., Takeuchi N., Toyota N.,
Kajima T., Nishimaru E. Gd!EOB!DTPA: When is transitional
period between distribution phase and hepatobiliary phase?
ECR. 2010; DOI 10.1594/ecr2010/C!0064.
25. Tanimoto A., Lee J.M., Murakami T., Huppertz A., Kudo M.,
Grazioli L. Consensus report of the 2nd International Forum for
Liver MRI. Eur. Radiol. 2009; 19 (5): 975–989.
26. Ha S.M., Lee C., Kim K.A., Lee J. Paradoxical uptake of Gd-EOB-DTPA of focal hepatic nodule in the hepatobiliary phase.
ECR. 2011; DOI 10.1594/ecr2011/C!1869.
27. Кармазановский Г.Г., Шимановский Н.Л. Улучшение диагностики заболеваний гепатобилиарной системы с помощью нового магнитно!резонансного контрастного препарата Примовист (гадоксетовая кислота). Мед. виз. 2006; 3: 123–134.
28. Zizka J., Klzo L., Ferda J., Mrklovsky M., Bukac J. Dynamic and
delayed contrast enhancement in upper abdominal MRI studies:
comparison of gadoxetic acid and gadobutrol. Eur. J. Radiol.
2007; 62 (2): 186–191.
29. Holzapfel K., Breitwieser C., Prinz C., Rummeny E.J., Gaa J.
Contrast!enhanced magnetic resonance cholangiography using
gadolinium!EOB!DTPA: preliminary experience and clinical
applications [in German]. Radiologe. 2007; 47 (6): 536–544.
30. Thomsen H.S., Marckmann P., Logager V.B. Nephrogenic systemic
fibrosis (NSF): a late adverse reaction to some of the gadolinium
based contrast agents. Cancer Imaging. 2007; 4 (7): 130–137.
31. Sonmez G., Sivrioglu A.K., Mutlu H. Is it possible to differentiate
between hydatid and simple cysts in the liver by means of diffusion-weighted magnetic resonance imaging? Clin. Imaging.
2012; 36 (1): 41–45.
32. Карпенко В.Н. Интервенционные вмешательства под контролем ультразвукового исследования в диагностике и лечении
очаговых образований печени. Вестник Российского научного центра рентгенорадиологии Федерального агентства по
высокотехнологичной медицинской помощи. 2009; 9: 4.
33. Бронштейн А.М., Малышев Н.А. Гельминтозы органов пищеварения: кишечные нематодозы, трематодозы печени и
ларвальные цестодозы (эхинококкозы). Российский медицинский журнал. 2004; 4: 208–211.
34. Runge V.M. Clinical MRI. USA. Theieme, 2002. Р. 289–352.
35. Лукьянченко А.Б., Медведева Б.М. Магнитно!резонансная
томография в диагностике и дифференциальной диагностике очаговых поражений печени. Вестник РОНЦ
им. Н.Н. Блохина. 2004; 15 (1–2): 68–72.
36. Seale M.K., Catalano O.A., Saini S., Hahn P.F., Sahani D.V.
Hepatobiliary!specific MR сontrast agents: role in imaging the
liver and biliary tree. RadioGraphics. 2009; 29 (6): 1725–1748.
37. Щеголев А.И., Тинькова И.О., Мишнев О.Д. Классификация
и морфологическая характеристика опухолей печени: доб!
рокачественные эпителиальные опухоли (лекция). Мед.
виз. 2006; 1: 29–38.
38. Gemer O., Moscovici O., Ben0Horin C.L., Moscovic O., Ben0
Horin C.L.D., Lina Linov L., Peled R., Segal S. Oral contraceptives and liver hemangioma: a case!control study. Acta Obstet.
Gynecol. Scand. 2004; 83 (12): 1199–1201.
39. Ringe K.I., Husarik D.B., Sirlin C.B., Merkle E.M. Gadoxetate
Disodium–Enhanced MRI of the Liver: Part 1, Protocol
Optimization and Lesion Appearance in the Noncirrhotic Liver.
Am. J. Roentgenol. 2010; 195 (1): 13–28.
40. Mergo P.J., Ros P.R. Benign lesions of the liver. Radiol. Clin.
North Am. 1998; 36 (2): 319–331.
41. Trastek V.F., Heerden J.A., Sheedy P.F. Cavernous hemangiomas
of the liver: resect or observe? Am. J. Surg. 1983; 145 (1): 49–53.
42. Reddy K.R., Kligerman S., Levi J., Livingstone A., Molina E.,
Franceschi D., Badalamenti S., Jeffers L., Tzakis A., Schiff E.R.
Benign and solid tumors of the liver: relationship to sex, age, size
of tumors, and outcome. Am. Surg. 2001; 67 (2): 173–178.
43. Matsuzaki K., Takeuchi K. Hepatic hemangiomas, and other
hemangiomatous tumors and tumor!like lesions: usual, unusual
imaging manifestations, pitfalls and problem!solving MR techniques. ECR. 2011; DOI 10.1594/ecr 2011/C!1900.
44. Huppertz A., Haraida S., Kraus A., Zech C.J., Scheidler J.,
Breuer J., Helmberger T.K., Reiser M.F. Enhancement of focal
liver lesions at gadoxetic acid!enhanced MR imaging: correlation with histopathologic findings and spiral CT!initial observations. Radiology. 2005; 234 (2): 468–478.
45. Brody J.M., Schafer L., Tung G.A., Breuer J., Shamsi K.
Conspicuity of liver hemangiomas: short tau inversion recovery, T1,
and T2 imaging with gadolinium ethoxybenzyl diethylenetriamine!
pentaacetic acid. J. Magn. Reson. Imaging. 2005; 21 (4): 391–397.
46. De Wilt J.H.W., Jzermans J.N.M. Массивные доброкачественные опухоли печени: фокальная нодулярная гиперплазия и
печеночно!клеточная аденома. Российский медицинский
журнал. 1997; 5 (2): 3.
47. Lizardi0Cervera J., Cuellar0Gamboa L., Motola0Kuba D. Focal
nodular hyperplasia and hepatic adenoma: a review. Ann.
Hepatol. 2006; 5 (3): 206–211.
48. Brown M.A., Semelka R.C. MRI: basic principles and application. Wiley-Liss, 1999. Р. 156–178.
49. Zech C.J., Grazioli L., Breuer J., Reiser M.F., Schoenberg S.O.
Diagnostic performance and description of morphological features of focal nodular hyperplasia in Gd!EOB!DTP Aenhanced
liver magnetic resonance imaging: results of a multicenter trial.
Invest. Radiol. 2008; 43 (1): 504–511.
50. Шерлок Ш., Дули Дж. Заболевания печени и желчных путей. М.: ГЭОТАР!МЕД, 2002. С. 413–417.
51. Federle P., Grazioli L., Nalesnik M. Hepatocellular adenoma:
multiphasic CT and histopathologic findings in 25 patients.
Radiology. 2000; 214 (3): 861–868.
52 James H.F., Martin M., Berman M.M. The malignant transformation of liver cell adenomas. Arch. Surg. 1994; 129 (7): 712–717.
53. Kudo M. Hepatocellular adenoma in type Ia glycogen storage
disease. J. Gastroent. 2001; 36 (1): 65–66.
54. Ba0Ssalamah A., Uffmann M., Saini S., Bastati N., Herold C.,
Schima W. Clinical value of MRI liver!specific contrast agents:
a tailored examination for a confident non!invasive diagnosis of
focal liver lesions. Eur. Radiol. 2009; 19 (2): 342–357.
55. Paulson E.K., McClellan J.S., Washington K., Spritzer C.E.,
Meyers W.C., Baker M.E. Hepatic adenoma: MR characteristics
and correlation with pathologic findings. Am. J. Roentgenol.
1994; 163 (1): 113–116.
56. Chung K.Y., Mayo0Smith W.W., Saini S., Rahmouni A., Golli M.,
Mathieu D. Hepatocellular adenoma: MR imaging features with
pathologic correlation. Am. J. Roentgenol. 1995; 165 (2):
303–308.
57. Ringe K.I., Husarik D.B., Sirlin C.B., Merkle E.M. Gadoxetate
Disodium–Enhanced MRI of the Liver: Part 2, Protocol
Optimization and Lesion Appearance in the Cirrhotic Liver. Am.
J. Roentgenol. 2010; 195 (1): 29–41.
58. Tanimoto A., Lee J.M., Murakami T., Huppertz A., Kudo M.,
Grazioli L. Consensus report of the 2nd international forum for
liver MRI. Eur. Radiol. 2009; 19 (5): 975–989.
59. Grazioli L., Morana G., Kirchin M.A., Schneider G. Accurate differentiation of focal nodular hyperplasia from hepatic adenoma
at gadobenate dimeglumine!enhanced MR imaging: prospective
study. Radiology. 2005; 236 (1): 166–177.
60. Boring C.C., Squires T.S., Tong T.T. Cancer statistics. CA Cancer.
J. Clin. Weiss H. 1994; 44 (1): 7–26.
61. Минаков Э.В., Шатов А.В., Ковалевская Е.М. Выявление очаговых поражений печени с помощью МР!томографии. Материалы научно-практической конференции. М., 1995. С. 57.
62. Синицын В.Е., Чуева Н.А. Дифференциальная диагностика
очаговых образований печени с помощью диффузной магнитно!резонансной томографии. Эксперимент. и клин. гастроэнтерол. 2010; 7: 131–139.
63. Lewis K.H., Chezmar J.L. Hepatic metastases. Magn. Reson.
Imaging. Clin. N. Am. 1997; 5 (2): 319–330.
64. Danet I.M., Semelka R.C., Leonardou P., Braga L., Vaidean G.,
Woosley J.T., Kanematsu M. Spectrum of MRI appearances of
untreated metastases of the liver. Am. J. Roentgenol. 2003; 181
(3): 809–817.
65. Stern W., Schick F., Kopp A.F., Reimer P., Shamsi K., Claussen C.D., Laniado M. Dynamic MR imaging of liver metastases
with Gd!EOB!DTPA. Acta Radiol. 2000; 41 (3): 255–262.
66. Hammerstingl R., Huppertz A., Breuer J., Balzer T., Blakeborough A., Carter R., Fuste L.C., Heinz0Peer G., Judmaier W.,
Laniado M., Manfredi R.M., Mathieu D.G., Muller D., Mortele K.,
Reimer P., Reiser M.F., Robinson P.J., Shamsi K., Strotzer M.,
Taupitz M., Tombach B., Valeri G., van Beers B.E., Vogl T.J.
Diagnostic efficacy of gadoxetic acid (Primovist)!enhanced
MRI and spiral CT for a therapeutic strategy: comparison with
intraoperative and histopathologic findings in focal liver lesions.
Eur. Radiol. 2008; 18 (3): 457–467.
67. Zech C.J., Herrmann K.A., Reiser M.F., Schoenberg S.O.
MR imaging in patients with suspected liver metastases: value of
liver!specific contrast agent Gd!EOBDTPA. Magn. Reson.
Med. Sci. 2007; 6 (1): 43–52.
68. Seidel R., Fries P., Farmakis G., Obst0Gleditsch K., Bucker A.,
Schneider G. MR evaluation of hepatic lesions after radioembolization by unenhanced and hepatobiliary phase MR imaging
using Gd!BOPTA ECR, EPOS 2011/C!1187.
69. Лукьянченко А.Б., Медведева Б.М., Подлужный Д.В. Первый
опыт применения гепатотропного МР!контрастного препарата Гадоксетовой кислоты (GD!EOB!DTPA) у больных
с метастазами колоректального рака в печени. Вестник
РОНЦ им. Н.Н. Блохина РАМН. 2009; 20: 3.
70. Bartolozzi C., Donati F., Cioni D., Procacci C., Morana G.,
Chiesa A., Grazioli L., Cittadini G., Cittadini G., Giovagnoni A.,
Gandini G., Maass J., Lencioni R. Detection of colorectal liver
metastases: a prospective multicenter trial comparing unenhanced MRI, MnDPDP!enhanced MRI, and spiral CT. Eur.
Radiol. 2004; 14 (1): 14–20.
71. Zech C.J., Grazioli L., Jonas E., Ekman M., Niebecker R., Gschwend
S., Breuer J., Jonsson L., Kienbaum S. Health!economic evaluation
of three imaging strategies in patients with suspected colorectal
liver metastases: Gd!EOB!DTPA!enhanced MRI vs. extracellular
contrast media!enhanced MRI and 3!phase MDCT in Germany,
Italy and Sweden. Eur. Radiol. 2009; 19 (3): 753–763.
72. Sherman M. Epidemiology of hepatocellular carcinoma.
Oncology. 2010; 78 (1): 7–10.
73. Golfieri R., Renzulli M., Lucidi V., Corcioni B., Trevisani F.,
Bolondi L. Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to Dynamic MRI in the detection of hypovascular small (≤2 cm) HCC in cirrhosis. Eur. Radiol. 2011; 21 (6):
1233–1242.
74. Shibuya K., Yano E. Regression analysis of trends in mortality
from hepatocellular carcinoma in Japan, 1972–2001. Int. J.
Epidemiol. 2005; 34 (2): 397–402.
75. Kogita S., Imai Y., Okada M., Kim T., Onishi H., Takamura M.,
Fukuda K., Igura T., Sawai Y., Morimoto O., Hori M., Nagano H.,
Wakasa K., Hayashi N., Murakami T. Gd-EOB-DTPA-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading and portal blood flow.
Eur. Radiol. 2010; 20 (10): 2405–2413.
76. Kim J.I., Lee J.M., Choi J.Y., Kim Y.K., Kim S.H., Lee J.Y.,
Han J.K., Choi B.I. The value of gadobenate dimeglumineenhanced delayed phase MR imaging for characterization of hepatocellular nodules in the cirrhotic liver. Invest. Radiol. 2008; 43 (3):
202–210.
77. Kitao A., Zen Y., Matsui O., Gabata T., Kobayashi S., Koda W.,
Kozaka K., Yoneda N., Yamashita T., Kaneko S., Nakanuma Y.
Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR imaging!correlation with molecular transporters
and histopathologic features. Radiology. 2010; 256 (3): 817–826.
78. Narita M., Hatano E., Arizono S., Miyagawa0Hayashino A.,
Isoda H., Kitamura K., Taura K., Yasuchika K., Nitta T., Ikai I.,
Uemoto S. Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J. Gastroenterol.
2009; 44 (7): 793–798.
79. Martin J., Puig J., Gil D., Darnell A., Malet A., Suarez D.
Hepatobiliary!phase signal intensity of hepatic nodules in Gd-EOB-DTPA-enhanced MRI does not correlate with histological
findings in cirrhotic patients. ECR. DOI 10.1594/ecr2010/B-387.
80. Kozaka K., Kobayashi S., Kitao A., Koda W., Minami T.,
Shinmura R., Kawai K., Gabata T., Matsui O. Detectability of
small hypervascular hepatocellular carcinoma using hepatobiliary phase of Gd!EOB!DTPA!enhanced MRI: Comparison
with CT during hepatic arteriography findings. ECR. DOI
10.1594/ecr2010/C!0049.
81. Quaia E., Ulcigrai V., Lorusso A., Cabibbo B., Cova M.A. The
MR imaging features of the hepatocellular carcinoma appearing
hypovascular on contrast!enhanced US and CT. ECR. DOI
10.1594/ecr2011/C!0894.
82. Ahn S.S., Kim M.J., Lim J.S., Hong H.S., Chung Y.E., Choi J.Y.
Added value of gadoxetic acid!enhanced hepatobiliary phase
MR imaging in the diagnosis of hepatocellular carcinoma.
Radiology. 2010; 255 (2): 459–466.
83. Landis S.H., Murray T., Bolden S., Wingo P.A. Cancer statistics.
CA Cancer J. Clin. 1998; 48 (1): 6–29.
84. Nakeeb A., Pitt H.A., Sohn T.A., Coleman J., Abrams R.A., Pianta-dosi S., Hruban R.H., Lillemoe K.D., Yeo C.J., Cameron J.L.
Cholangiocarcinoma: a spectrum of intrahepatic, perihilar, and
distal tumors. Ann. Surg. 1996; 224 (4): 463–473.
85. Olnes M.J., Erlich R. A review and update on cholangiocarcinoma. Oncology. 2004; 66 (3): 167–179.
86. Bergquist A., Ekbom A., Olsson R., Kornfeldt D., Loof L.,
Danielsson A., Hultcrantz R., Lindgren S., Prytz H., Sandberg-Gertzen H., Almer S., Granath F., Broome U. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J.
Hepatol. 2002; 36 (3): 321–327.
87. Chung Y.E., Kim M.J., Park Y.N., Choi J.Y., Pyo J.Y., Kim Y.C.,
Cho H.J., Kim K.A., Choi S.Y. Varying appearances of cholangiocarcinoma: radiologic!pathologic correlation. RadioGraphics.
2009; 29 (3): 683–700.
88. Worawattanakul S., Semelka R.C., Noone T.C., Calvo B.F.,
Kelekis N.L., Woosley J.T. Cholangiocarcinoma: spectrum of
appearances on MR images using current techniques. Magn.
Reson. Imaging. 1998; 16 (9): 993–1003.
89. Дондеро Ф., Маеда А., Киаманеш Р., Вилграйн В., Бельгити Ж. Желчные пути. Лечение холангиокарциномы. Анн.
хир. гепатол. 2003; 8 (1): 47–52.
90. Dolgushin B., Sergeeva O.N., Panov V. et al. Gd!EOB-DTPA-enhanced MRI assessement of intraductal photodynamic therapy action in hilar cholangiocarcinoma patients. ECR, EPOS
2011; C!1059.
91. Ringe K.I., Husarik D.B., Gupta R.T., Boll D.T., Merkle E.M.

The Value of the Liver Tissue-Specific MRI Contrast Agent Primovist in the Differential Diagnosis of the Focal Liver and Bile Ducts Diseases

Keywords: